Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer
Status:
Terminated
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
OncoGel is a new experimental drug delivery system that allows the slow continuous release of
paclitaxel (an approved intravenous anticancer drug), from a gel (ReGel) over a long period
of time. The gel will disappear in 4 to 6 weeks as it releases the paclitaxel.
The protocol is directed towards evaluating the efficacy and safety of paclitaxel delivered
as a local, intralesional treatment when used in combination with chemotherapy (cisplatin and
5-FU) and radiation therapy before surgery.